logo Hematology/Oncology Research Studies: Open for Enrollment Date: 01/26/21

Category: ONCOLOGY

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

NCT#/Phase: NCT02176967
Phase 3
IRB#: 2014-051
Description: This Phase III trial in patients with non-high-risk neuroblastoma or ganglioneuroblastoma continues a response and biology based treatment approach utilized on prior studies, but patient subgroups will be further refined using histologic and genomic criteria, and therapy modified accordingly. Patients will be assigned to the appropriate treatment group based on the patientís age, tumor stage and biologic features of International Neuroblastoma Pathology Classification (INPC) histology and genomic features (MCYN status, DNA ploidy and genomic profile).
Inclusion:
Enrollment Status: Open for enrollment
Sponsor: COG
Principal Investigator(s): Carla Golden, MD
Contact(s): Sheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT02176967

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000